YEZTUGO is the first-and-only PrEP option that offers twice-yearly, in-office subcutaneous injections1-4
Confirm HIV-negative status prior to injecting YEZTUGO and additionally as clinically appropriate. In addition, counsel individuals about the importance of adherence to scheduled YEZTUGO dosing visits.1
Initiating YEZTUGO1
See additional information on delayed or missed doses
aTablets may be taken with or without food.
bUnless the injection schedule is interrupted.
Dosing recommendations for individuals receiving YEZTUGO and initiating therapy with1:
Maintain scheduled continuation injection dosing
Continue to administer once-every-6-months scheduled continuation dosing of YEZTUGO 927 mg subcutaneously (2 x 1.5-mL injections), plus administer supplemental doses of YEZTUGO as shown in table below.
Schedule for supplemental doses of YEZTUGO
| Time | Dosage |
|---|---|
| On day that strong CYP3A inducer is initiated (should be at least 2 days after YEZTUGO is first initiated) | Supplemental dosage: Step 1 927 mg subcutaneously (2 x 1.5-mL injections) AND 600 mg orally (2 x 300-mg tablets) |
| On day after initiation of strong CYP3A inducer | Supplemental dosage: Step 2 600 mg orally (2 x 300-mg tablets) |
| If strong CYP3A inducer is coadministered for longer than 6 months | Subsequent supplemental dosage: Every 6 monthsd from initiation of strong CYP3A inducer, continue to administer supplemental doses of YEZTUGO as described above in Steps 1 and 2 |
After stopping the strong CYP3A inducer, continue the once-every-6-months scheduled continuation injection dosing of YEZTUGO.
cDosing recommendations are not available for the initiation of YEZTUGO in individuals already receiving strong CYP3A inducers, nor in individuals receiving the weekly oral dosage of YEZTUGO (for more information, see: Anticipated delayed injections below).
d26 weeks ±2 weeks.
Maintain scheduled continuation injection dosing
Continue to administer once-every-6-months scheduled continuation dosing of YEZTUGO 927 mg subcutaneously (2 x 1.5-mL injections), plus administer supplemental doses of YEZTUGO as shown in table below.
Schedule for supplemental doses of YEZTUGO
| Time | Dosage |
|---|---|
| On day that moderate CYP3A inducer is initiated | Supplemental dosage: 463.5 mg subcutaneously (1 x 1.5-mL injection) |
| If moderate CYP3A inducer is coadministered for longer than 6 months | Subsequent supplemental dosage: Every 6 monthsf from initiation of moderate CYP3A inducer, continue to administer a supplemental dose of YEZTUGO as described above |
After stopping the moderate CYP3A inducer, continue the once-every-6-months scheduled continuation injection dosing of YEZTUGO.
eDosing recommendations are not available for the initiation of YEZTUGO in individuals already receiving moderate CYP3A inducers, nor in individuals receiving the weekly oral dosage of YEZTUGO (for more information, see: Anticipated delayed injections below).
f26 weeks ±2 weeks.
What if there is a delayed or missed dose?1-3
Missed oral initiation dose
If an individual misses the Day 2 oral initiation dose (600 mg), have them take it as soon as possible. Instruct them not to take Day 1 and Day 2 oral initiation doses on the same day.
Anticipated delayed injections
During continuation dosing, if the scheduled 6-month injection is anticipated to be delayed by more than 2 weeks, YEZTUGO tablets may be taken.
- One 300-mg oral tablet may be taken once each week (every 7 days) for up to 6 months, until injections resume
- Resume the continuation injection dosing within 1 week (7 days) after the last oral dose
Missed injections
If an individual misses a scheduled injection visit by more than 28 weeks, they should be clinically reassessed to ensure they’re appropriate to resume YEZTUGO and that they remain HIV-1 negative.
- If no YEZTUGO oral tablets have been taken and it has been more than 28 weeks since last injection, restart initiation dosing, then proceed with continuation injections
- Adherence to the injection dosing schedule is strongly recommended
Please see Prescribing Information for additional details.
Multiple ways to acquire YEZTUGO
There are several ways your office may acquire
YEZTUGO for the individuals in your care.
Important resources for your office
Access materials and support to help initiate individuals in your practice on YEZTUGO, along with helpful resources for your staff and practice.
References:
- YEZTUGO. Prescribing information. Gilead Sciences, Inc.; 2025.
- Bekker LG, Das M, Abdool Karim Q, et al; PURPOSE 1 study team. Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women. N Engl J Med. 2024;391(13):1179-1192.
- Kelley CF, Acevedo-Quiñones M, Agwu AL, et al; PURPOSE 2 study team. Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons. N Engl J Med. 2025;392(13):1261-1276.
- Full efficacy and safety results for Gilead investigational twice-yearly lenacapavir for HIV prevention presented at AIDS 2024. News release. Gilead Sciences, Inc.; July 24, 2024. Accessed January 6, 2025. https://www.gilead.com/news/news-details/2024/full-efficacy-and-safety-results-for-gilead-investigational-twice-yearly-lenacapavir-for-hiv-prevention-presented-at-aids-2024
- Wang H, Guan J, Zhang X, et al. Effect of cold application on the pain and bruising in patients with subcutaneous injection of low-molecular-weight heparin: a meta-analysis. Clin Appl Thromb Hemost. 2020;26:1076029620905349.
- Rava J, Rosenau KA, Wilkie K, Bernacki J, Curcio E, Kuo A. The needle anxiety program: a patient-centered initiative for individuals with developmental disabilities. Cureus. 2023;16(7):e42253.
- Sivri Bilgen B, Balci S. The effect on pain of Buzzy® and ShotBlocker® during the administration of intramuscular injections to children: a randomized controlled trial. J Korean Acad Nurs. 2019;49(4):486-494.